PPARA and depressive symptom measurement: Since PPARα is also implicated in the pathophysiology of several other neurological disorders (e.g. stroke, Alzheimer’s disease, Parkinson’s disease and epilepsy) besides depression (Bordet et al., 2006; Fidaleo et al., 2014; D'Orio et al., 2018), vortioxetine may possess more beneficial efficacy involving PPARα in the central nervous system.